In bile duct-ligated (BDL) rats, large cholangiocytes proliferate by activation of cAMP-dependent signaling. Melatonin, which is secreted from pineal gland as well as extrapineal tissues, regulates cell mitosis by interacting with melatonin receptors (MT1 and MT2) modulating cAMP and clock genes. In the liver, melatonin suppresses oxidative damage and ameliorates fibrosis. No information exists regarding the role of melatonin in the regulation of biliary hyperplasia. We evaluated the mechanisms of action by which melatonin regulates the growth of cholangiocytes. In normal and BDL rats, we determined the hepatic distribution of MT1, MT2, and the clock genes, CLOCK, BMAL1, CRY1, and PER1. Normal and BDL (immediately after BDL) rats were treated in vivo with melatonin before evaluating 1) serum levels of melatonin, bilirubin, and transaminases; 2) intrahepatic bile duct mass (IBDM) in liver sections; and 3) the expression of MT1 and MT2, clock genes, and PKA phosphorylation. In vitro, large cholangiocytes were stimulated with melatonin in the absence/presence of luzindole (MT1/ MT2 antagonist) and 4-phenyl-2-propionamidotetralin (MT2 antagonist) before evaluating cell proliferation, cAMP levels, and PKA phosphorylation. Cholangiocytes express MT1 and MT2, CLOCK, BMAL1, CRY1, and PER1 that were all upregulated following BDL. Administration of melatonin to BDL rats decreased IBDM, serum bilirubin and transaminases levels, the expression of all clock genes, cAMP levels, and PKA phosphorylation in cholangiocytes. In vitro, melatonin decreased the proliferation, cAMP levels, and PKA phosphorylation, decreases that were blocked by luzindole. Melatonin may be important in the management of biliary hyperplasia in human cholangiopathies.
ized by cholangiocyte hyperplasia/damage (5) that is restricted to bile ducts of certain sizes (3, 40) . In BDL rats only large cholangiocytes (lining large ducts) (2, 6, 23) proliferate (leading to enhanced large intrahepatic bile ductal mass, IBDM) (3, 40) by the activation of cAMP¡PKA signaling (3, 24, 40) . Studies (4, 24, 40, 42) have demonstrated the key role of secretin and its receptor (SR, only expressed by cholangiocytes in rodent liver) (2, 8, 24) in the regulation and functional evaluation of biliary hyperplasia/damage. Following BDL the enhanced biliary hyperplasia is associated with increased SR expression and secretin-stimulated cAMP levels and bile secretion (3, 4, 7, 8, 40, 42) . Conversely, during damage of cholangiocytes, there is reduced SR expression and functional response to secretin (40, 41) . A number of neuroendocrine factors and neuropeptides such as secretin, sex hormones, vascular endothelial growth factor, ␣-calcitonin gene-related peptide, serotonin, cholinergic and adrenergic receptor agonists, and biogenic amines have been shown to exert inhibitory and/or stimulatory effects on biliary growth in normal and cholestatic conditions (3, 5, 9, 20 -22, 24, 39, 42) .
Melatonin is an indole formed enzymatically from L-tryptophan by the activity of the enzymes serotonin N-acetyltransferase (AANAT), and hydroxyindole-0-methyltransferase (32, 37) and is produced predominantly by the pineal gland (53) . Extrapineal sites (e.g., the gastrointestinal tract) of melatonin production have been demonstrated (13) . Melatonin exerts its effects by interacting with G protein-coupled membrane receptors, such as melatonin 1A receptor (MT1), MT2, and MT3 (found only in nonmammals) (37, 55) , modulating intracellular messengers such as cAMP, a key molecule regulating large cholangiocyte functions (40) , and [Ca 2ϩ ] i , an important signaling molecule regulating the function of small cholangiocytes (21) . Indeed, melatonin-activation of G protein-coupled receptors inhibits cAMP levels in a number of cells including rat pancreatic ␤-cells (50) .
Melatonin receptors are distributed in the central nervous system (46) as well as in peripheral tissues including small intestine and hepatocytes (45, 51) . In the liver, melatonin suppresses oxidative damage, attenuates proliferation, and stimulates apoptosis of hepatocytes in rats subjected to partial hepatectomy (35) . Melatonin improves liver fibrosis in rats with BDL (62) and ameliorates BDL-induced systemic oxidative stress in cholestatic rats (19) . No information exists re-garding the role and mechanisms of action by which melatonin modulates biliary hyperplasia in cholestatic rats. Melatonin regulates cell mitosis by modulation of the circadian rhythm, which is under the control of a core set of clock genes: Period 1, 2, and 3 (PER1-3); Cryptochrome 1 and 2 (CRY1 and CRY2); CLOCK; and BMAL1 and BMAL2 (33) . For example, melatonin exerts antiproliferative effects in breast cancer cells by resynchronization of deregulated core clock circuitry (27) . The aims of the study were to demonstrate in the BDL rats that 1) melatonin decreases the proliferation of large cholangiocytes and liver damage and 2) melatonin inhibition of large biliary hyperplasia is associated with downregulation of cAMP-dependent phosphorylation of PKA and modulation of clock genes.
METHODS AND MATERIALS
Materials. Reagents were purchased from Sigma Chemical (St. Louis, MO) unless otherwise indicated. The following antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA): 1) mouse monoclonal antibody against rat proliferating cell nuclear antigen (PCNA); 2) MT1, an affinity-purified goat polyclonal antibody raised against a peptide mapping near the COOH terminus of MT1 of rat origin; 3) MT2, an affinity-purified goat polyclonal antibody raised against a peptide mapping within an internal region of MT2 of mouse origin; and 4) the rabbit polyclonal antibodies to the CLOCK transcription factor, the goat polyclonal antibody to BMAL1 transcription factor, CRY1, and PER1 proteins. The mouse anticytokeratin-19 (CK-19) antibody was purchased from Caltag Laboratories (Burlingame, CA). The phospho-PKA catalytic subunit antibody was purchased from Cell Signaling (Boston, MA). The RNeasy Mini Kit to purify RNA was purchased from Qiagen (Valencia, CA). The radioimmunoassay (RIA) kits for the determination of cAMP levels were purchased from GE Healthcare (Arlington Heights, IL). 4-Phenyl-2-propionamidotetralin (4-P-PDOT, a specific MT2 antagonist, Ͼ300-fold selective for the MT2 vs. the MT1 subtype) (61) and the MT1/MT2 antagonist, luzindole (18) , were purchased from Tocris Bioscience, Ellisville, MO.
Animal models. Male 344 Fischer rats (150 -175 g) were purchased from Charles River (Wilmington, MA) and kept in a temperaturecontrolled environment (22°C) with 12-h:12-h light/dark cycles. Animals were fed ad libitum and had free access to food and drinking water. The studies were performed in normal rats and in rats that, immediately after BDL (4) or bile duct incannulation (BDI, for bile collection) (4), had ad libitum access to water or water containing melatonin (20 mg/l corresponding to a melatonin intake of 2 mg/g body wt per day) (10) for 1 wk (Table 1) . Melatonin (20 mg) was dissolved in 2.5 ml of ethanol and then diluted at 1 l with water. Control animals received water containing the same amount of ethanol. This estimated intake of melatonin is based on the fact that rats drink ϳ15 ml of water per day mostly throughout the night (57) when melatonin secretion from the pineal gland is higher (37) . The facts that 1) circulating melatonin is mostly metabolized (4 -6 h in rats) (56) and excreted with the bile to small bowel and returns to the liver through enterohepatic circulation (with a minimal quantity excreted through the urine) (37, 65) and that 2) melatonin serum levels increased in our model (see Table 1 ) support the validity of our route of melatonin administration. The administration of melatonin by drinking water has been previously used in rodents (10) . Before each surgical procedure, animals were anesthetized with pentobarbital sodium (50 mg/kg body wt ip). All animal experiments were performed in accordance with a protocol approved by the Scott and White and Texas A&M HSC IACUC Committee. All animals were used for the harvest of tissues and purification of liver cells at 8:00 AM. In all animals, we measured wet liver weight, body weight, and wet liver weight-to-body weight ratio, an index of cell growth (4). Expression of MT1 and MT2, CLOCK, BMAL1, CRY1, and PER1 in liver sections and purified cholangiocytes. We evaluated the expression of MT1 and MT2 and CLOCK, BMAL1, CRY1, and PER1 in liver sections (4 -5 m thick) from normal and BDL rats by immunohistochemistry (42) and in total RNA (0.5 g) by real-time PCR (21) from purified cholangiocytes.
Immunohistochemical observations were taken in a coded fashion by BX-51 light microscopy (Olympus, Tokyo, Japan) with a Videocam (Spot Insight; Diagnostic Instrument, Sterling Heights, MI) and analyzed with an Image Analysis System (Delta Sistemi, Rome, Italy). For all immunoreactions, negative controls (with normal serum from the same species substituted for the primary antibody) were included. To evaluate the expression of the messages for MT1 and MT2, CLOCK, BMAL1, CRY1, and PER1, we used the RT 2 Real-Time assay from SABiosciences (Frederick, MD) (21) . A ⌬⌬CT analysis was performed (21) using normal cholangiocytes as control. Data were expressed as relative mRNA levels Ϯ SE of the selected gene-to-GAPDH ratio. The primers for melatonin receptors 1A and 1B, CLOCK, BMAL1, CRY1, and PER1 (SABiosciences) were designed according to the NCBI GenBank Accession numbers: XM_341441 (MT1), NM_053330 (MT2), NM_021856 (CLOCK gene), NM_024362 (BMAL1 gene), NM_198750 (CRY1), and NM_001034125 (PER1).
We evaluated by fluorescence-activated cell sorting (FACS) analysis (49) the expression of MT1 and MT2, CLOCK, BMAL1, CRY1, and PER1 in purified large cholangiocytes. FACS analysis was performed using a C6 flow cytometer and analyzed by CFlow Software (Accuri Cytometers, Ann Arbor, MI) (49) . The expression of the selected protein was identified and gated on FL1-A/Count plots. The relative quantity of the selected protein (mean selected protein fluorescence) was expressed as mean FL1-A (samples)/mean FL-1A (secondary antibodies only).
Isolated and immortalized large cholangiocytes. The isolation of cholangiocytes started each morning at 8:00 AM. Pure (100% by ␥-glutamyltransferase histochemistry) (58) cholangiocytes were isolated by immunoaffinity separation (7) using a monoclonal antibody (from Dr. R. Faris, Brown University, Providence, RI). The rationale for performing these studies in large cholangiocytes is based on the fact that, following BDL, only these cells undergo mitosis (3, 23, 40) . The in vitro studies were performed in immortalized large cholangiocytes (from large bile ducts) (63) displaying phenotypes similar to that of freshly isolated cholangiocytes (3, 21, 24, 63) .
Evaluation of serum levels of melatonin, transaminases, and bilirubin and cholangiocyte proliferation and apoptosis. The serum levels of the transaminases, glutamate pyruvate transaminases, and glutamic oxaloacetic transaminase and total bilirubin were evaluated using a Dimension RxL Max Integrated Chemistry system (Dade Behring, Deerfield, IL) by the Chemistry Department, Scott & White. Serum levels of melatonin were measured by commercially available ELISA kits (Genway, San Diego, CA).
We evaluated in liver sections (4 -5 m thick) 1) the percentage of cholangiocyte proliferation by semiquantitative immunolocalization for PCNA (41) , 2) IBDM of cholangiocytes (41) , and 3) the percentage of cholangiocyte apoptosis by semiquantitative terminal deoxynucleotidyltransferase biotin-dUTP nick-end labeling (TUNEL) kit (Apoptag; Chemicon International, Temecula, CA) (24) . We evaluated by hematoxylin and eosin of sections whether melatonin administration induces the damage of kidney, heart, stomach, spleen, and small and large intestine. Sections were evaluated in a blinded fashion by a BX-51 light microscope (Olympus, Tokyo, Japan).
Measurement of PCNA expression and phosphorylation of PKA. We evaluated by immunoblots (21) PCNA protein expression (21) and the phosphorylation of PKA in protein (10 g) from spleen (positive) and large cholangiocytes from melatonin-or vehicle-treated BDL rats. The intensity of the bands was determined by scanning video densitometry using the phospho-imager Storm 860 and the ImageQuant TL software version 2003.02 (GE Healthcare).
Measurement of secretin-stimulated cAMP levels and bile and bicarbonate secretion. We evaluated the effect of secretin on cAMP levels in large cholangiocytes and bile and bicarbonate secretion in Fig. 1 . A: by immunohistochemistry in liver sections, bile ducts (yellow arrow) from normal rats (NR) were weakly positive for melatonin 1A receptor (MT1) and did not stain for MT2; bile ducts (yellow arrows) from bile duct-ligated (BDL) rats showed immunoreactivity for both MT1 and MT2. Original magnification ϫ20. B: expression of CLOCK and BMAL1 was virtually absent in normal bile ducts; immunoreactivity was observed in BDL bile ducts (yellow arrows). Normal bile ducts stained positively for PER1 and CRY1, whose expression increased in bile ducts from BDL rats. Original magnification ϫ20. C: by real-time PCR, the mRNA expression of PER1, BMAL1, CRY1, and CLOCK increased in BDL compared with normal cholangiocytes but decreased in cholangiocytes from normal and BDL rats treated with melatonin in vivo compared with control cholangiocytes. D: by fluorescence-activated cell sorting (FACS) analysis, the protein expression of PER1, BMAL1, CRY1, and CLOCK decreased in cholangiocytes from BDL rats treated with melatonin in vivo compared with cholangiocytes from BDL rats treated with vehicle. Data are means Ϯ SE of 3 evaluations. *P Ͻ 0.05 vs. the values of normal cholangiocytes. #P Ͻ 0.05 vs. the values of normal and BDL cholangiocytes from rats treated with regular tap water. bile fistula rats. Following isolation, cholangiocytes (1 ϫ 10 5 cells) were incubated for 1 h at 37°C (31) before stimulation with 0.2% bovine serum albumin or secretin (100 nM) for 5 min at room temperature before evaluation of cAMP levels by RIA (3, 40) . After anesthesia, rats were surgically prepared for bile collection (4). When steady-state bile flow was reached (60 -70 min from the intravenous infusion of Krebs-Ringer-Henseleit solution, KRH), the animals were infused with secretin (100 nM) (39, 40) for 30 min followed by intravenous infusion of KRH for 30 min. Bicarbonate levels in bile were determined by a COBAS Mira Plus automated clinical chemistry analyzer (Bohemia, NY) (47) .
In vitro effect of melatonin on the proliferation of large cholangiocytes. We evaluated by immunofluorescence (21) and immunoblots (20) the expression of MT1 and MT2 receptors in immortalized large cholangiocytes. Images were visualized using an Olympus IX-71 confocal microscope. For all immunoreactions, negative controls were included. The intensity of the bands was determined by scanning video densitometry (see above).
We evaluated by RIA kits (3, 34, 40) cAMP levels in cholangiocytes treated with vehicle (basal) or melatonin (10 Ϫ11 M for 5 min) in the absence/presence of preincubation with 4-P-PDOT or luzindole (both 10 M) (18, 61) . The rationale for using this dose (10 Ϫ11 M) for melatonin is based on the finding that serum levels of melatonin in rodents and humans are on the picomolar to nanomolar ranges (12, 66) . After trypsinization, cholangiocytes were treated at 37°C for 48 h with vehicle (DMSO diluted with 1ϫ PBS), melatonin (10 Ϫ11 M) in the absence/presence of preincubation with 4-P-PDOT or luzindole (10 M) (18, 61), 4-P-PDOT or luzindole alone (10 M) before evaluating by immunoblots (21) the expression of PCNA and PKA phosphorylation. Melatonin was first dissolved in DMSO and then diluted with 1ϫ PBS at the stock solution of 2.5 ϫ 10 Ϫ2 M before being diluted to the desired working solution with 1ϫ PBS.
Statistical analysis. All data are expressed as means Ϯ SE. Differences between groups were analyzed by Student's unpaired t-test when two groups were analyzed and ANOVA when more than two groups were analyzed, followed by an appropriate post hoc test.
RESULTS

Cholangiocytes express MT1 and MT2, CLOCK, BMAL1, CRY1
, and PER1. By immunohistochemistry in liver sections, normal bile ducts were weakly positive for MT1 (but not MT2) but showed strong immunoreactivity for MT1 and MT2 following BDL (Fig. 1A) . The expression of CLOCK and BMAL1 was absent in normal bile ducts; however, immunoreactivity was observed in BDL bile ducts (Fig. 1B) . Normal bile ducts stained positively for PER1 and CRY1, whose expression slightly increased in bile ducts from BDL rats (Fig.  1B) . By real-time PCR and FACS analysis (Fig. 1, C and D) , the expression of PER1, BMAL1, CRY1, and CLOCK increased in BDL compared with normal cholangiocytes but decreased in cholangiocytes from normal and BDL rats treated in vivo with melatonin compared with control cholangiocytes. The mRNA expression of MT1 and MT2 increased in BDL compared with normal cholangiocytes (Fig. 2A) . By real-time PCR and FACS analysis, the expression of MT1 and MT2 decreased in cholangiocytes from BDL rats treated with melatonin in vivo compared with cholangiocytes from control BDL (Fig. 2, A and B) . Fig. 3 . Effect of melatonin on large intrahepatic bile duct mass (IBDM) of BDL rats, immunoreactivity for CK19. The administration of melatonin to BDL rats decreased IBDM compared with their corresponding controls rats (for semiquantitative data see Table 2 ) (yellow arrows: bile ducts) Original magnification, ϫ20.
Evaluation of serum levels of melatonin and transaminases, and bilirubin levels, cholangiocyte proliferation, and apoptosis.
There was a 15-20% decrease of body weight in BDL compared with normal rats (Table 1) . No difference was observed in body weight between normal and BDL rats treated with melatonin compared with controls (Table 1) . There was a decrease in liver-to-body weight ratio in BDL rats treated with melatonin compared with BDL controls (Table 1 ). The serum levels of melatonin of normal rats were similar to that of previous studies and increased following BDL (64) and after the administration of melatonin to normal and BDL rats ( Table  1 ). The serum levels of transaminases increased in BDL rats compared with normal rats and were decreased in both normal and BDL rats by the administration of melatonin ( Table 1 ). The administration of melatonin to BDL rats decreased large BDM ( Fig. 3 and Table 2 ) and the percentage of PCNA-positive cholangiocytes (Table 2 ) compared with control rats. Melatonin inhibition of biliary hyperplasia in BDL rats was associated with enhanced cholangiocyte apoptosis ( Table 2) . Melatonin had no effects in normal rats (Table 2) . No morphological changes of kidney, heart, stomach, spleen, and small and large intestine were observed in rats treated with melatonin (not shown).
Effect of secretin on cAMP levels in cholangiocytes and bile and bicarbonate secretion in bile fistula rats. In BDL rats treated with melatonin, basal levels of cAMP and basal bile and bicarbonate secretion were lower than those of the corresponding values of BDL control rats (Fig. 4A and Table 3 ). As expected (7), secretin increased cAMP levels of large cholangiocytes from BDL rats but did not enhance the levels of cAMP of large cholangiocytes from BDL rats treated with melatonin for 1 wk (Fig. 4A) . Secretin increased bile and bicarbonate secretion of BDL controls but not of melatonintreated BDL rats (Table 3) .
Effect of melatonin on the expression of PCNA and phosphorylation of PKA in large cholangiocytes. There was decreased PCNA expression in large cholangiocytes from BDL rats treated with melatonin compared with cholangiocytes from BDL control rats (Fig. 4B) . We found decreased phosphorylation of PKA in large cholangiocytes from melatonin-treated BDL rats compared with large cholangiocytes from BDL controls (Fig. 4C) .
Effect of melatonin on the proliferation of large cholangiocytes. By immunofluorescence and immunoblots, large cholangiocytes express both MT1 and MT2 (Fig. 5, left and right) . Melatonin decreased cAMP levels, a decrease that was prevented by luzindole (a MT1/MT2 antagonist) (18) but not 4-P-PDOT (a specific MT2 antagonist) (61) (Fig. 6A) , demonstrating that melatonin inhibitory effects on cholangiocyte growth are mediated by MT1. Melatonin decreased gene and protein expression for PCNA and the phosphorylation of PKA, decreases that were prevented by luzindole but not 4-P-PDOT (Fig. 6, B-D) . Neither luzindole nor 4-P-PDOT alters cholangiocyte proliferation (not shown). By FACS analysis, in vitro melatonin decreased the expression of PER1, BMAL1, CRY1, and CLOCK ( Fig. 7A ) and MT1 and MT2 (Fig. 7B ) compared with their corresponding basal value.
DISCUSSION
Our study demonstrated 1) that freshly isolated and lines of large cholangiocytes express MT1 and MT2, CLOCK, BMAL1, CRY1, and PER1 and 2) that in vivo administration of melatonin to BDL rats reduces the serum levels of transaminases and bilirubin and inhibits cholangiocyte proliferation and IBDM typical of BDL (4). The antiproliferative effects of melatonin on biliary growth were associated with decreased basal cAMP levels and spontaneous bile and bicarbonate secretion as well as with loss of responsiveness to secretin and enhanced biliary apoptosis. The biliary expression of MT1 and MT2 and clock genes increased in BDL compared with normal cholangiocytes and decreased in cholangiocytes from normal and BDL rats treated with melatonin. There was decreased phosphorylation of PKA in cholangiocytes. In vitro melatonin decreased proliferation, cAMP levels, and PKA phosphorylation in large cholangiocytes, decreases that were mediated by MT1 receptors.
As it mimics typical features of human cholangiopathies (5), the BDL model is commonly used for evaluating the mechanisms of biliary growth/damage (3, 4, 24) . Cholangiopathies share common pathological characteristics such as the damage of cholangiocytes and the proliferation of residual ducts (as a mechanism of compensatory repair to maintain the homeostasis of the biliary tree) (9), but they evolve toward ductopenia that represents the terminal stage of these diseases (9) .
We provided the first evidence for the presence of functional melatonin receptors in the biliary epithelium. A recent study showing that melatonin attenuates the damage caused by scolicidal agents on bile ducts alluded to the presence of melatonin receptors on cholangiocytes (60) . MT1s are expressed by human gallbladder epithelia (11) . The reason why these inhibitory melatonin receptors are upregulated in proliferating BDL cholangiocytes may be due to a compensatory mechanism. The decrease in the expression of MT1 and MT2 by melatonin is likely due to desensitization of these receptors as suggested by other studies (36) . Another explanation may be due to the increased expression of AANAT (the enzyme regulating melatonin secretion by cholangiocytes, G. Alpini, unpublished observations), an increase that may lead to decreased expression of melatonin receptors. Studies are being undertaken in our laboratory to demonstrate the presence and role of this autocrine loop (AANAT¡MT1/MT2) in the autocrine regulation of biliary growth.
The validity of our model was supported by the fact that, following chronic administration of melatonin, the serum levels of this hormone increased compared with BDL control rats. The serum levels of melatonin in normal rats were similar to that of previous studies (30) and, in agreement with previous findings (e.g., in liver cirrhosis) (14) , increased following BDL. The finding that administration of melatonin to normal and BDL rats increases its circulating levels is supported by studies in rats (52) and humans (17) . A number of studies support the inhibitory effect of melatonin on cell mitosis. For example, melatonin inhibits the hyperplastic growth of gastric mucosal in rats (1) . The finding that the in vivo administration of melatonin decreases the serum levels of transaminases and bilirubin (observed in BDL rats) is supported by previous studies (48) . This finding suggests that melatonin protects the biliary epithelium from cholestatic injury as supported by the fact that melatonin ameliorates oxidative stress in cholestatic rats (19) .
We demonstrated that melatonin inhibition of biliary hyperplasia is associated with downregulation of basal and secretinstimulated cAMP levels and bile secretion and phosphorylation of PKA, regulators of large cholangiocyte proliferation (3, 40 -42) . Indeed, activation of cAMP-dependent signaling has been shown to stimulate large cholangiocyte hyperplasia (22, 24) . Conversely, downregulation of the cAMP-dependent transduction pathway inhibits BDL-induced biliary hyperplasia (20, 40) .
We performed in vitro experiments in large cholangiocytes aimed to demonstrate that melatonin exerts its effects by direct interaction with specific melatonin receptors (MT1) by downregulating cAMP signaling and selected clock genes. The concept that MT1 (but not MT2) is the predominant receptor modulating the inhibitory effects of melatonin on biliary hyperplasia is supported by studies in other cells (43, 50) . These findings raise the potential important concept that drug targeting of MT1 may be important in the management of cholangiopathies.
Recent studies have demonstrated the role of circadian rhythm (26) and the key circadian hormone, melatonin, in the pathogenesis of disease states and carcinogenesis (54, 59) . Several studies have implicated melatonin in the pathogenesis of liver disease and damage. Melatonin synthesis, release, and resulting circadian rhythms are dysregulated in a number of liver diseases. Abnormal melatonin circadian rhythms are found in patients with hepatic cirrhosis and correlated with the severity of liver insufficiency (64) . This melatonin arrhythmia is corrected after liver transplantation (15) . In addition, melatonin has been shown to protect against liver damage by attenuating oxidative stress and apoptosis in animal models of hepatic cirrhosis and fibrosis (16, 28, 29) . Melatonin regulates the expression of circadian genes, which include Per1 and Per2, Cry1 and Cry2, BMAL1, and CLOCK. Circadian genes are linked with downregulation of cell proliferation and dysregulation of cell-cycle control during carcinogenesis (38) . Mice lacking the circadian genes Per1 and Per2 and Cry1 and Cry2 are deficient in cell-cycle regulation, and Per2 mutant mice are cancer prone (38) . Studies have shown that clock genes regulate cell mitosis and that melatonin regulates cell proliferation by changes in clock gene expression (27) . For example, the circadian clock component BMAL1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation (25) . The loss of CLOCK activity in Cry1 Ϫ/Ϫ / Cry2 Ϫ/Ϫ double mutant mice results in delayed liver regeneration (44) . Supporting these studies, we have demonstrated that melatonin inhibition of biliary hyperplasia is associated with downregulation of PER1, CLOCK, BMAL1, and CRY1 expression. These previous findings suggest that circadian genes play a key role in the mechanisms regulating liver cell proliferation, and our current findings suggest that clock genes may play an important role in liver pathogenesis. Future studies are necessary to fully elucidate the individual roles of each circadian gene in the proliferative signaling cascade by which melatonin regulates biliary proliferation. Studies aimed to evaluate the expression and function of clock genes in cholangiocytes in vivo over at least one full 24-h cycle are undergoing because melatonin secretion from the pineal gland (37) and the biliary epithelium (G. Alpini unpublished observations) is higher during the night. Our findings have important clinical implications because melatonin (an over-the-counter drug used for curing sleep disorders) may be an important therapeutic tool for managing the cholangiocyte hyperplasia in biliary disorders.
